MétaCan
Menu
Back to cohort
Record W2201163923 · doi:10.1371/journal.pone.0145772

HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance Testing

2015· article· en· W2201163923 on OpenAlexaff
Soo‐Yon Rhee, Michael R. Jordan, Elliot Raizes, Arlene Chua, Neil Parkin, Rami Kantor, Gert U. van Zyl, Irene Mukui, Mina C. Hosseinipour, Lisa M. Frenkel, Nicaise Ndembi, Raph L Hamers, Tobias F. Rinke de Wit, Carole L. Wallis, Ravindra K. Gupta, Joseph Fokam, Clement Zeh, Jonathan Schapiro, Sergio Carmona, David Katzenstein, Michele W. Tang, Avelin F. Aghokeng, Túlio de Oliveira, Annemarie M. J. Wensing, Joel E. Gallant, Mark A. Wainberg, Douglas D. Richman, Joseph Fitzgibbon, Marco Schito, Silvia Bertagnolio, Chunfu Yang, Robert W. Shafer

Bibliographic record

VenuePLoS ONE · 2015
Typearticle
Languageen
FieldMedicine
TopicHIV/AIDS drug development and treatment
Canadian institutionsMcGill UniversityJewish General Hospital
FundersCenters for Disease Control and PreventionNational Institutes of HealthWellcome TrustU.S. President’s Emergency Plan for AIDS ReliefWorld Health OrganizationNational Institute of Allergy and Infectious DiseasesBill and Melinda Gates Foundation
KeywordsResistance mutationDrug resistanceHIV drug resistanceGenotypeVirologyViral loadMedicineReverse-transcriptase inhibitorRegimenLentivirusBiologyReverse transcriptaseHuman immunodeficiency virus (HIV)Antiretroviral therapyInternal medicinePolymerase chain reactionGeneticsViral disease

Abstract

fetched live from OpenAlex

The increasing prevalence of acquired and transmitted HIV-1 drug resistance is an obstacle to successful antiretroviral therapy (ART) in the low- and middle-income countries (LMICs) hardest hit by the HIV-1 pandemic. Genotypic drug resistance testing could facilitate the choice of initial ART in areas with rising transmitted drug resistance (TDR) and enable care-providers to determine which individuals with virological failure (VF) on a first- or second-line ART regimen require a change in treatment. An inexpensive near point-of-care (POC) genotypic resistance test would be useful in settings where the resources, capacity, and infrastructure to perform standard genotypic drug resistance testing are limited. Such a test would be particularly useful in conjunction with the POC HIV-1 viral load tests that are currently being introduced in LMICs. A POC genotypic resistance test is likely to involve the use of allele-specific point mutation assays for detecting drug-resistance mutations (DRMs). This study proposes that two major nucleoside reverse transcriptase inhibitor (NRTI)-associated DRMs (M184V and K65R) and four major NNRTI-associated DRMs (K103N, Y181C, G190A, and V106M) would be the most useful for POC genotypic resistance testing in LMIC settings. One or more of these six DRMs was present in 61.2% of analyzed virus sequences from ART-naïve individuals with intermediate or high-level TDR and 98.8% of analyzed virus sequences from individuals on a first-line NRTI/NNRTI-containing regimen with intermediate or high-level acquired drug resistance. The detection of one or more of these DRMs in an ART-naïve individual or in a individual with VF on a first-line NRTI/NNRTI-containing regimen may be considered an indication for a protease inhibitor (PI)-containing regimen or closer virological monitoring based on cost-effectiveness or country policy.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: none
Teacher disagreement score0.413
Threshold uncertainty score0.513

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.049
GPT teacher head0.260
Teacher spread0.211 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations95
Published2015
Admission routes1
Has abstractyes

Explore more

Same venuePLoS ONESame topicHIV/AIDS drug development and treatmentFrench-language works237,207